Cargando…

Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting

The use of targeted therapeutics known as poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the management of ovarian cancer is currently transforming clinical practice. The PARP inhibitor rucaparib is indicated in the UK, European Union and the United States for use in the treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Tookman, Laura, Krell, Jonathan, Nkolobe, Baleseng, Burley, Laura, McNeish, Iain A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7257860/
https://www.ncbi.nlm.nih.gov/pubmed/32523631
http://dx.doi.org/10.1177/1758835920921980
_version_ 1783540072238284800
author Tookman, Laura
Krell, Jonathan
Nkolobe, Baleseng
Burley, Laura
McNeish, Iain A.
author_facet Tookman, Laura
Krell, Jonathan
Nkolobe, Baleseng
Burley, Laura
McNeish, Iain A.
author_sort Tookman, Laura
collection PubMed
description The use of targeted therapeutics known as poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the management of ovarian cancer is currently transforming clinical practice. The PARP inhibitor rucaparib is indicated in the UK, European Union and the United States for use in the treatment and maintenance settings for patients with relapsed ovarian cancer. Here, we discuss some of the real-world challenges and side effects that we have encountered while prescribing rucaparib, and we provide practical guidance on how the individual members of our multidisciplinary team (MDT), including a clinician, chemotherapy nurse practitioner, and clinical pharmacist, collaborate to manage these side effects. If recognized early, the side effects experienced by patients during rucaparib therapy, which include fatigue, nausea and vomiting, liver enzyme elevations, and anemia, can be easily managed. For example, providing patients with prophylactic antiemetics can help them avoid nausea, and early detection of decreases in hemoglobin levels allows for proactive interventions to alleviate anemia. The MDT should work together with the patient to identify potential side effects early and manage them effectively. The aim of this proactive approach is to maintain patients on rucaparib for optimal clinical benefit, while minimizing the potential negative impact of side effects on patient quality of life.
format Online
Article
Text
id pubmed-7257860
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-72578602020-06-09 Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting Tookman, Laura Krell, Jonathan Nkolobe, Baleseng Burley, Laura McNeish, Iain A. Ther Adv Med Oncol Review The use of targeted therapeutics known as poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the management of ovarian cancer is currently transforming clinical practice. The PARP inhibitor rucaparib is indicated in the UK, European Union and the United States for use in the treatment and maintenance settings for patients with relapsed ovarian cancer. Here, we discuss some of the real-world challenges and side effects that we have encountered while prescribing rucaparib, and we provide practical guidance on how the individual members of our multidisciplinary team (MDT), including a clinician, chemotherapy nurse practitioner, and clinical pharmacist, collaborate to manage these side effects. If recognized early, the side effects experienced by patients during rucaparib therapy, which include fatigue, nausea and vomiting, liver enzyme elevations, and anemia, can be easily managed. For example, providing patients with prophylactic antiemetics can help them avoid nausea, and early detection of decreases in hemoglobin levels allows for proactive interventions to alleviate anemia. The MDT should work together with the patient to identify potential side effects early and manage them effectively. The aim of this proactive approach is to maintain patients on rucaparib for optimal clinical benefit, while minimizing the potential negative impact of side effects on patient quality of life. SAGE Publications 2020-05-27 /pmc/articles/PMC7257860/ /pubmed/32523631 http://dx.doi.org/10.1177/1758835920921980 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Tookman, Laura
Krell, Jonathan
Nkolobe, Baleseng
Burley, Laura
McNeish, Iain A.
Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting
title Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting
title_full Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting
title_fullStr Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting
title_full_unstemmed Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting
title_short Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting
title_sort practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary uk setting
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7257860/
https://www.ncbi.nlm.nih.gov/pubmed/32523631
http://dx.doi.org/10.1177/1758835920921980
work_keys_str_mv AT tookmanlaura practicalguidanceforthemanagementofsideeffectsduringrucaparibtherapyinamultidisciplinaryuksetting
AT krelljonathan practicalguidanceforthemanagementofsideeffectsduringrucaparibtherapyinamultidisciplinaryuksetting
AT nkolobebaleseng practicalguidanceforthemanagementofsideeffectsduringrucaparibtherapyinamultidisciplinaryuksetting
AT burleylaura practicalguidanceforthemanagementofsideeffectsduringrucaparibtherapyinamultidisciplinaryuksetting
AT mcneishiaina practicalguidanceforthemanagementofsideeffectsduringrucaparibtherapyinamultidisciplinaryuksetting